Skip to main content
Top
Published in: Tumor Biology 4/2016

01-04-2016 | Original Article

Evaluation of prognostic factors in localized high-grade undifferentiated pleomorphic sarcoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology

Published in: Tumor Biology | Issue 4/2016

Login to get access

Abstract

Most data on prognostic factors for patients with high-grade undifferentiated pleomorphic sarcoma (HGUPS) is obtained from analyses of soft tissue sarcomas. The purpose of this study was to evaluate the clinicopathologic features and their impact on outcomes specifically in patients diagnosed with HGUPS. In this multicenter trial, we retrospectively analyzed 112 patients who were diagnosed and treated at 12 different institutions in Turkey. We collected data concerning the patients, tumor characteristics, and treatment modalities. There were 69 males (61.6 %) and 43 females (38.4 %). Median age was 56 years (19–90). The most common anatomic site of tumor origin was the upper extremity. Pleomorphic variant was the predominant histological subtype. Median tumor size was 8.2 cm (0.6–30 cm). Tumors were mainly deeply seated (57.1 %). Fifty-seven patients (50.9 %) were stage II and the remainder were stage III at the time of diagnosis. Median follow-up was 30 months (2–160). The primary site of distant metastasis was the lung (73.5 %) and the second most common site was the liver (11.7 %). The 5-year overall survival, distant metastasis-free survival, and local recurrence-free survival rates were 56.3, 53.4, and 67.2 %, respectively. Multivariate analysis showed that Eastern Cooperative Oncology Group (ECOG) performance score of II (p = 0.033), deep tumor location (p = 0.000), and development of distant metastasis (p = 0.004) were negatively correlated with overall survival, and perioperative radiotherapy and negative microscopic margins were significant factors for local control rates (p = 0.000 for each). Deep tumor location (p = 0.003) was the only adverse factor related to distant metastasis-free survival. Deep tumor location, ECOG performance score of II, and development of distant metastasis carry a poor prognostic implication on overall survival. These will aid clinicians in predicting survival and treatment decision.
Literature
2.
go back to reference Dei Tos AP. Classification of pleomorphic sarcomas: where are we now? Histopathology. 2006;48:51–62.CrossRefPubMed Dei Tos AP. Classification of pleomorphic sarcomas: where are we now? Histopathology. 2006;48:51–62.CrossRefPubMed
3.
go back to reference Massi D, Beltrami G, Capanna R, Franchi A. Histopathological re-classification of extremity pleomorphic soft tissue sarcoma has clinical relevance. Eur J Surg Oncol. 2004;30:1131–6.CrossRefPubMed Massi D, Beltrami G, Capanna R, Franchi A. Histopathological re-classification of extremity pleomorphic soft tissue sarcoma has clinical relevance. Eur J Surg Oncol. 2004;30:1131–6.CrossRefPubMed
4.
go back to reference Fletcher CD. The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology. 2006;48:3–12.CrossRefPubMed Fletcher CD. The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology. 2006;48:3–12.CrossRefPubMed
5.
go back to reference Kearney MM, Soule EH, Ivins JC. Malignant fibrous histiocytoma: a retrospective study of 167 cases. Cancer. 1980;45:167–78.CrossRefPubMed Kearney MM, Soule EH, Ivins JC. Malignant fibrous histiocytoma: a retrospective study of 167 cases. Cancer. 1980;45:167–78.CrossRefPubMed
6.
go back to reference Weiss SW, Enzinger FM. Malignant fibrous histiocytoma: an analysis of 200 cases. Cancer. 1978;41:2250–66.CrossRefPubMed Weiss SW, Enzinger FM. Malignant fibrous histiocytoma: an analysis of 200 cases. Cancer. 1978;41:2250–66.CrossRefPubMed
7.
go back to reference Leite C, Goodwin JW, Sinkovics JG, Baker LH, Benjamen R. Chemotherapy of malignant fibrous histiocytoma. A Southwest Oncology Group Report. Cancer. 1977;40:2010–14.CrossRefPubMed Leite C, Goodwin JW, Sinkovics JG, Baker LH, Benjamen R. Chemotherapy of malignant fibrous histiocytoma. A Southwest Oncology Group Report. Cancer. 1977;40:2010–14.CrossRefPubMed
8.
go back to reference Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS, et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer. 2003;97(10):2530–43.CrossRefPubMed Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS, et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer. 2003;97(10):2530–43.CrossRefPubMed
9.
go back to reference Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchere D, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 2001;91(10):1914–26.CrossRefPubMed Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchere D, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 2001;91(10):1914–26.CrossRefPubMed
10.
go back to reference Toulmonde M, Le Cesne A, Mendiboure J, Blay JY, Piperno-Neumann S, Chevreau C, et al. Long-term recurrence of soft tissue sarcomas: prognostic factors and implications for prolonged follow-up. Cancer. 2014;120(19):3003–6.CrossRefPubMed Toulmonde M, Le Cesne A, Mendiboure J, Blay JY, Piperno-Neumann S, Chevreau C, et al. Long-term recurrence of soft tissue sarcomas: prognostic factors and implications for prolonged follow-up. Cancer. 2014;120(19):3003–6.CrossRefPubMed
11.
go back to reference Maretty-Nielsen K, Aggerholm-Pedersen N, Safwat A, Jørgensen PH, Hansen BH, Baerentzen S, et al. Prognostic factors for local recurrence and mortality in adult soft tissue sarcoma of the extremities and trunk wall: a cohort study of 922 consecutive patients. Acta Orthop. 2014;85(3):323–32.CrossRefPubMedPubMedCentral Maretty-Nielsen K, Aggerholm-Pedersen N, Safwat A, Jørgensen PH, Hansen BH, Baerentzen S, et al. Prognostic factors for local recurrence and mortality in adult soft tissue sarcoma of the extremities and trunk wall: a cohort study of 922 consecutive patients. Acta Orthop. 2014;85(3):323–32.CrossRefPubMedPubMedCentral
12.
go back to reference Salcedo Hernández RA, Lino-Silva LS, de León DC, Herrera-Gómez Á, Martinez-Said H, Meneses-Garcia A. Importance of tumor size in soft tissue sarcomas: a proposal for a nomogram based on a score system to staging soft tissue sarcomas in the postoperative setting. Med Oncol. 2014;31(3):873.CrossRefPubMed Salcedo Hernández RA, Lino-Silva LS, de León DC, Herrera-Gómez Á, Martinez-Said H, Meneses-Garcia A. Importance of tumor size in soft tissue sarcomas: a proposal for a nomogram based on a score system to staging soft tissue sarcomas in the postoperative setting. Med Oncol. 2014;31(3):873.CrossRefPubMed
13.
go back to reference Jones NB, Iwenofu H, Scharschmidt T, Kraybill W. Prognostic factors and staging for soft tissue sarcomas: an update. Surg Oncol Clin N Am. 2012;21(2):187–200.CrossRefPubMed Jones NB, Iwenofu H, Scharschmidt T, Kraybill W. Prognostic factors and staging for soft tissue sarcomas: an update. Surg Oncol Clin N Am. 2012;21(2):187–200.CrossRefPubMed
14.
go back to reference Kempson RL, Kyriakos M. Fibroxanthosarcoma of the soft tissues—a type of malignant fibrous histiocytoma. Cancer. 1972;29:961–76.CrossRefPubMed Kempson RL, Kyriakos M. Fibroxanthosarcoma of the soft tissues—a type of malignant fibrous histiocytoma. Cancer. 1972;29:961–76.CrossRefPubMed
15.
go back to reference Weiss SW, Enzinger FM. Myxoid variant of malignant fibrous histiocytoma. Cancer. 1977;39:1672–85.CrossRefPubMed Weiss SW, Enzinger FM. Myxoid variant of malignant fibrous histiocytoma. Cancer. 1977;39:1672–85.CrossRefPubMed
16.
go back to reference Le Doussal V, Coindre JM, Leroux A, Hacene K, Terrier P, Bui NB, et al. Prognostic factors for patients with localized primary malignant fibrous histiocytoma: a multicenter study of 216 patients with multivariate analysis. Cancer. 1996;77(9):1823–30.CrossRefPubMed Le Doussal V, Coindre JM, Leroux A, Hacene K, Terrier P, Bui NB, et al. Prognostic factors for patients with localized primary malignant fibrous histiocytoma: a multicenter study of 216 patients with multivariate analysis. Cancer. 1996;77(9):1823–30.CrossRefPubMed
17.
go back to reference Rööser B, Willén H, Gustafson P, Alvegård TA, Rydholm A. Malignant fibrous histiocytoma of soft tissue: a population-based epidemiologic and prognostic study of 137 patients. Cancer. 1991;67:499–505.CrossRefPubMed Rööser B, Willén H, Gustafson P, Alvegård TA, Rydholm A. Malignant fibrous histiocytoma of soft tissue: a population-based epidemiologic and prognostic study of 137 patients. Cancer. 1991;67:499–505.CrossRefPubMed
18.
go back to reference Oda Y, Tamiya S, Oshiro Y, Hachitanda Y, Kinukawa N, Iwamoto Y, et al. Reassessment and clinicopathological prognostic factors of malignant fibrous histiocytoma of soft parts. Pathol Int. 2002;52(9):595–606.CrossRefPubMed Oda Y, Tamiya S, Oshiro Y, Hachitanda Y, Kinukawa N, Iwamoto Y, et al. Reassessment and clinicopathological prognostic factors of malignant fibrous histiocytoma of soft parts. Pathol Int. 2002;52(9):595–606.CrossRefPubMed
19.
go back to reference Pezzi CM, Rawlings MS, Esgro JJ, Pollock RE. Prognostic factors in 227 patients with malignant fibrous histiocytoma. Cancer. 1992;69:2098–103.CrossRefPubMed Pezzi CM, Rawlings MS, Esgro JJ, Pollock RE. Prognostic factors in 227 patients with malignant fibrous histiocytoma. Cancer. 1992;69:2098–103.CrossRefPubMed
20.
go back to reference Belal A, Kandil A, Allam A, Khafaga Y. Malignant fibrous histiocytoma: a retrospective study of 109 cases. Am J Clin Oncol. 2002;25:16–22.CrossRefPubMed Belal A, Kandil A, Allam A, Khafaga Y. Malignant fibrous histiocytoma: a retrospective study of 109 cases. Am J Clin Oncol. 2002;25:16–22.CrossRefPubMed
21.
go back to reference Engellau J, Persson A, Bendahl PO, Akerman M, Domanski HA, Bjerkehagen B, et al. Expression profiling using tissue microarray in 211 malignant fibrous histiocytomas confirms the prognostic value of Ki-67. Virchows Arch. 2004;445(3):224–30.CrossRefPubMed Engellau J, Persson A, Bendahl PO, Akerman M, Domanski HA, Bjerkehagen B, et al. Expression profiling using tissue microarray in 211 malignant fibrous histiocytomas confirms the prognostic value of Ki-67. Virchows Arch. 2004;445(3):224–30.CrossRefPubMed
22.
go back to reference Vasileios KA, Eward WC, Brigman BE. Surgical treatment and prognosis in patients with high-grade soft tissue malignant fibrous histiocytoma of the extremities. Arch Orthop Trauma Surg. 2012;132(7):955–61.CrossRefPubMed Vasileios KA, Eward WC, Brigman BE. Surgical treatment and prognosis in patients with high-grade soft tissue malignant fibrous histiocytoma of the extremities. Arch Orthop Trauma Surg. 2012;132(7):955–61.CrossRefPubMed
23.
go back to reference Hsu HC, Huang EY, Wang CJ. Treatment results and prognostic factors in patients with malignant fibrous histiocytoma. Acta Oncol. 2004;43(6):530–5.CrossRefPubMed Hsu HC, Huang EY, Wang CJ. Treatment results and prognostic factors in patients with malignant fibrous histiocytoma. Acta Oncol. 2004;43(6):530–5.CrossRefPubMed
24.
go back to reference Li GX, Guo W. Analysis of therapeutic strategies and prognostic factors of malignant fibrous histiocytoma of soft tissue. Zhonghua Wai Ke Za Zhi. 2011;49(11):974–7.PubMed Li GX, Guo W. Analysis of therapeutic strategies and prognostic factors of malignant fibrous histiocytoma of soft tissue. Zhonghua Wai Ke Za Zhi. 2011;49(11):974–7.PubMed
25.
go back to reference Kim MS, Cho WH, Song WS, Lee SY, Jeon DG. Prognostic significance of ezrin expression in pleomorphic malignant fibrous histiocytoma. Anticancer Res. 2007;27:1171–8.PubMed Kim MS, Cho WH, Song WS, Lee SY, Jeon DG. Prognostic significance of ezrin expression in pleomorphic malignant fibrous histiocytoma. Anticancer Res. 2007;27:1171–8.PubMed
26.
go back to reference Lehnhardt M, Daigeler A, Homann HH, Schwaiberger V, Goertz O, Kuhnen C, et al. MFH revisited: outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities—an analysis of 140 patients. Langenbecks Arch Surg. 2009;394(2):313–20.CrossRefPubMed Lehnhardt M, Daigeler A, Homann HH, Schwaiberger V, Goertz O, Kuhnen C, et al. MFH revisited: outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities—an analysis of 140 patients. Langenbecks Arch Surg. 2009;394(2):313–20.CrossRefPubMed
27.
go back to reference Antman KH. Adjuvant therapy of sarcomas of soft tissue. Semin Oncol. 1997;24(5):556–60.PubMed Antman KH. Adjuvant therapy of sarcomas of soft tissue. Semin Oncol. 1997;24(5):556–60.PubMed
28.
go back to reference Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19(5):1238–47.CrossRefPubMed Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19(5):1238–47.CrossRefPubMed
29.
go back to reference Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573–81.CrossRefPubMed Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573–81.CrossRefPubMed
Metadata
Title
Evaluation of prognostic factors in localized high-grade undifferentiated pleomorphic sarcoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology
Publication date
01-04-2016
Published in
Tumor Biology / Issue 4/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4359-1

Other articles of this Issue 4/2016

Tumor Biology 4/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine